Comparative Pharmacology
Head-to-head clinical analysis: HYDROXYSTILBAMIDINE ISETHIONATE versus PENTAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXYSTILBAMIDINE ISETHIONATE versus PENTAM.
HYDROXYSTILBAMIDINE ISETHIONATE vs PENTAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxystilbamidine isethionate is an antiprotozoal agent that inhibits nucleic acid synthesis and disrupts polyamine metabolism by binding to DNA and RNA, particularly in kinetoplasts of Leishmania species.
Pentamidine is an antiprotozoal agent that interferes with nucleotide and nucleic acid synthesis, possibly by binding to DNA and inhibiting RNA and protein synthesis. It also affects membrane integrity and inhibits oxidative phosphorylation.
2-4 mg/kg/day intravenously every 24 hours for visceral leishmaniasis; 2-4 mg/kg intramuscularly every 24 hours for cutaneous leishmaniasis.
4 mg/kg intravenously once daily for 21 days (Pneumocystis jirovecii pneumonia); or 300 mg deep intramuscularly every 3 weeks for prophylaxis.
None Documented
None Documented
Clinical Note
moderatePentamidine + Gatifloxacin
"Pentamidine may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderatePentamidine + Rosoxacin
"Pentamidine may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderatePentamidine + Trovafloxacin
"Pentamidine may increase the hypoglycemic activities of Trovafloxacin."
Clinical Note
moderatePentamidine + Nalidixic acid
"Pentamidine may increase the hypoglycemic activities of Nalidixic acid."
Terminal half-life: 24-48 hours; clinically, elimination is multiphasic with a slow tissue redistribution phase, requiring cautious dosing to avoid accumulation.
Terminal elimination half-life: 6-24 hours (prolonged in renal impairment; up to 48 hours in anuria).
Renal: 10-15% as unchanged drug; biliary/fecal: 80-90% as metabolites and unchanged drug; negligible glomerular filtration due to high protein binding; prolonged presence in tissues.
Renal: approximately 60-70% unchanged; biliary/fecal: minimal, <10%.
Category C
Category C
Antiprotozoal Agent
Antiprotozoal Agent